Disulfiram/Cu Kills and Sensitizes BRAF -Mutant Thyroid Cancer Cells to BRAF Kinase Inhibitor by ROS...
Disulfiram/Cu Kills and Sensitizes BRAF -Mutant Thyroid Cancer Cells to BRAF Kinase Inhibitor by ROS-Dependently Relieving Feedback Activation of MAPK/ERK and PI3K/AKT Pathways
About this item
Full title
Author / Creator
Xie, Jingyi , Liu, Juan , Zhao, Man , Li, Xinru , Wang, Yubo , Zhao, Yuelei , Cao, Hongxin , Ji, Meiju , Chen, Mingwei and Hou, Peng
Publisher
Switzerland: MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: MDPI AG
Subjects
More information
Scope and Contents
Contents
, the most common genetic alteration, has become a major therapeutic target in thyroid cancer. Vemurafenib (PLX4032), a specific inhibitor of
kinase, exhibits antitumor activity in patients with
-mutated thyroid cancer. However, the clinical benefit of PLX4032 is often limited by short-term response and acquired resistance via heterogeneous f...
Alternative Titles
Full title
Disulfiram/Cu Kills and Sensitizes BRAF -Mutant Thyroid Cancer Cells to BRAF Kinase Inhibitor by ROS-Dependently Relieving Feedback Activation of MAPK/ERK and PI3K/AKT Pathways
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9968072
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9968072
Other Identifiers
ISSN
1422-0067,1661-6596
E-ISSN
1422-0067
DOI
10.3390/ijms24043418
